The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicitySara Caratelli, Giuseppe Sconocchia, Giulia Lanzilli et al.|Experimental Hematology and Oncology|2025Cited by 4
The CD64/CD28/CD3 ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicitySara Caratelli, Giuseppe Sconocchia, Francesca De Paolis et al.|Research Square|2024Cited by 0
A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trialChiara Sartor, Antonio Curti, Anna Candoni et al.|Blood|2025Cited by 0